Paul Hughes - one job buddy ( Si has PH name on screen)
Language- stuck to the script re after additional consideration trial data appears sufficient to refile.
Later Si referred to " after approval" for kids , then we would run a adult/adolescent trial - single arm (insert @whytee shrieking ) - failed Rux- picking up 40% of the severe market in which the current outcome is patients die.
Imminent refiling this quarter of the BLA
Dosing first patient in the CLBP trial this quarter mentioned again with FDA approval of the product if we meet the 12 month pain reduction primary.
Reg
Presentation on ASX Gems Conference on 21st June, page-99
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |